Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386437055> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W4386437055 endingPage "196" @default.
- W4386437055 startingPage "186" @default.
- W4386437055 abstract "Introduction and aim. Nowadays, the increasing resistance of bacteria is a concerning and challenging issue in terms of effective treatment of bacterial infections. The amount of available antibiotics has been quite constant for many years. The search for substances alternative to older classes of drugs, among which resistance is growing, has been ongoing for years. One of the newly introduced available alternatives is lefamulin. The aim of this paper is to present the potential benefits of its use in comunity-acquired bacterial pneumonia (CABP). 
 Material and methods. A review of the available literature was performed by searching the PubMed and GoogleScholar databases using the following key words: lefamulin; BC3781; pleuromutilin; CABP; community acquired pneumonia.
 Analysis of literature. Lefamulin is a bacteriostatic antibiotic from the group of pleuromutilins, which has a unique mechanism of action consisting in binding to the bacterial 50S ribosomal subunit in the peptidyl transferase center. Thanks to this, it rarely causes resistance among other groups of antibiotics and is characterized by a safe action profile. Its spectrum of action includes bacteria causing CABP. In phase III studies, the efficacy of lefamulin monotherapy was comparable to that of moxifloxacin with or without linezolid in CABP. Thanks to broad spectrum of action its usefulness may also extend to treatment of methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and multidrug-resistant organisms associated with sexually transmitted infections, e.g., Neisseria gonorrhoeae, Mycoplasma genitalium, although more additional clinical and pharmacodynamic data is needed.
 Conclusion. Lefamulin is a promising addition to the antibiotic armamentarium for treating CABP. Its unique mechanism of action, activity against typical and atypical bacteria, flexible dosing options, and favorable safety profile make it a beneficial choice for clinicians." @default.
- W4386437055 created "2023-09-05" @default.
- W4386437055 creator A5013098147 @default.
- W4386437055 creator A5016374806 @default.
- W4386437055 creator A5041246221 @default.
- W4386437055 creator A5051498241 @default.
- W4386437055 creator A5065749723 @default.
- W4386437055 date "2023-09-05" @default.
- W4386437055 modified "2023-10-16" @default.
- W4386437055 title "Lefamulin - a recently developed antibiotic for treatment of community-acquired bacterial pneumonia (CABP)" @default.
- W4386437055 doi "https://doi.org/10.12775/jehs.2023.15.01.018" @default.
- W4386437055 hasPublicationYear "2023" @default.
- W4386437055 type Work @default.
- W4386437055 citedByCount "0" @default.
- W4386437055 crossrefType "journal-article" @default.
- W4386437055 hasAuthorship W4386437055A5013098147 @default.
- W4386437055 hasAuthorship W4386437055A5016374806 @default.
- W4386437055 hasAuthorship W4386437055A5041246221 @default.
- W4386437055 hasAuthorship W4386437055A5051498241 @default.
- W4386437055 hasAuthorship W4386437055A5065749723 @default.
- W4386437055 hasBestOaLocation W43864370551 @default.
- W4386437055 hasConcept C2776345407 @default.
- W4386437055 hasConcept C2777677444 @default.
- W4386437055 hasConcept C2778836808 @default.
- W4386437055 hasConcept C2778980435 @default.
- W4386437055 hasConcept C2779166590 @default.
- W4386437055 hasConcept C2779489039 @default.
- W4386437055 hasConcept C2781414143 @default.
- W4386437055 hasConcept C501593827 @default.
- W4386437055 hasConcept C523546767 @default.
- W4386437055 hasConcept C54355233 @default.
- W4386437055 hasConcept C71924100 @default.
- W4386437055 hasConcept C86803240 @default.
- W4386437055 hasConcept C89423630 @default.
- W4386437055 hasConcept C94665300 @default.
- W4386437055 hasConceptScore W4386437055C2776345407 @default.
- W4386437055 hasConceptScore W4386437055C2777677444 @default.
- W4386437055 hasConceptScore W4386437055C2778836808 @default.
- W4386437055 hasConceptScore W4386437055C2778980435 @default.
- W4386437055 hasConceptScore W4386437055C2779166590 @default.
- W4386437055 hasConceptScore W4386437055C2779489039 @default.
- W4386437055 hasConceptScore W4386437055C2781414143 @default.
- W4386437055 hasConceptScore W4386437055C501593827 @default.
- W4386437055 hasConceptScore W4386437055C523546767 @default.
- W4386437055 hasConceptScore W4386437055C54355233 @default.
- W4386437055 hasConceptScore W4386437055C71924100 @default.
- W4386437055 hasConceptScore W4386437055C86803240 @default.
- W4386437055 hasConceptScore W4386437055C89423630 @default.
- W4386437055 hasConceptScore W4386437055C94665300 @default.
- W4386437055 hasIssue "1" @default.
- W4386437055 hasLocation W43864370551 @default.
- W4386437055 hasLocation W43864370552 @default.
- W4386437055 hasOpenAccess W4386437055 @default.
- W4386437055 hasPrimaryLocation W43864370551 @default.
- W4386437055 hasRelatedWork W1998827564 @default.
- W4386437055 hasRelatedWork W2018382434 @default.
- W4386437055 hasRelatedWork W2069442553 @default.
- W4386437055 hasRelatedWork W2179124794 @default.
- W4386437055 hasRelatedWork W2326830576 @default.
- W4386437055 hasRelatedWork W2590516909 @default.
- W4386437055 hasRelatedWork W3032641156 @default.
- W4386437055 hasRelatedWork W3125557516 @default.
- W4386437055 hasRelatedWork W3195958508 @default.
- W4386437055 hasRelatedWork W3429368 @default.
- W4386437055 hasVolume "15" @default.
- W4386437055 isParatext "false" @default.
- W4386437055 isRetracted "false" @default.
- W4386437055 workType "article" @default.